Sentiment Trading

Septerna Inc has partnered with Novo Nordisk in a $2.2 billion deal, positioning the company as a leader in the obesity treatment market with its innovative oral drugs.

Septerna Inc. and Novo Nordisk have announced a $2.2 billion collaboration to develop innovative oral small molecule medicines targeting obesity, type 2 diabetes, and cardiometabolic diseases.